Clinical Information Search
Search Results for "diabetes_articles"
- Online Learning Center (0)
- Policy Library (103)
- Performance Measures (0)
- Annals of Internal Medicine (1952)
- Annals of Internal Medicine: Clinical Cases (143)
- IM Matters (6)
- ACP Hospitalist (42)
- ACP Diabetes Monthly (58)
- ACP Gastroenterology Monthly (4)
Sorry, no results were found for "diabetes_articles" in Online Learning Center.
Sorry, no results were found for "diabetes_articles" in Performance Measures.
Displaying 211 - 220 of 1952 in Annals of Internal Medicine
These Annals of Internal Medicine results only contain recent articles.
- Visit annals.org to search all content back to 1927.
- View Annals of Internal Medicine CME by topic here.
In insulin-treated type 1 diabetes, canagliflozin increased diabetic ketoacidosis
Source Citation Peters AL, Henry RR, Thakkar P, Tong C, Alba M. Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care. 2016;39:532-8. 26989182
In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosis
Source Citation Mathieu C, Zinman B, Hemmingsson JU, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: The ADJUNCT ONE treat-to-target randomized trial. Diabetes Care. 2016;39:1702-10. 27506222
Review: In adults with diabetes, aspirin does not prevent CV events compared with placebo
Source Citation Kunutsor SK, Seidu S, Khunti K. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabet Med. 2016. [Epub ahead of print]. 27086572
In abstinent adults with type 2 diabetes, a daily glass of wine (vs mineral water) improved cardiometabolic factors
Source Citation Gepner Y, Golan R, Harman-Boehm I, et al. Effects of initiating moderate alcohol intake on cardiometabolic risk in adults with type 2 diabetes: a 2-year randomized, controlled trial. Ann Intern Med. 2015;163:569-79. 26458258
In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years
Source Citation Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;Sep 17. [Epub ahead of print.] 26378978
Review: In diabetes, benefits of lowering BP depend on baseline BP being 140 mm Hg or more
Source Citation Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352:i717. 26920333
Diabetes and other comorbid conditions were associated with a poor outcome in SARS | ACP Journal Club
Source Citation Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:2801-9. 12734147
Simvastatin reduced mortality and vascular events in diabetes mellitus | ACP Journal Club
Source Citation Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-16. 12814710
In type 2 diabetes, tirzepatide reduced HbA1c vs. semaglutide
Source Citation Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503-15. 34170647
In type 1 diabetes, real-time vs. intermittently scanned continuous glucose monitoring improved glycemic control
Source Citation Visser MM, Charleer S, Fieuws S, et al. Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial. Lancet. 2021;397:2275-83. 34089660